10-K: Lunai Bioworks Faces Mounting Losses, Subsidiary Bankruptcy

Lunai Bioworks Inc. reported a significant increase in net loss for fiscal year 2025, alongside a subsidiary's bankruptcy and ongoing legal challenges, raising substantial doubt about its ability to continue as a going concern.

Summary

• Lunai Bioworks Inc. (formerly Renovaro Inc.) reported a net loss of $178,007,489 for the fiscal year ended June 30, 2025, a 101% increase from $88,425,828 in the prior year.
• The company's cash and cash equivalents decreased to $92,700 as of June 30, 2025, from $220,467 in the previous year.
• An accumulated deficit reached $510,462,570 as of June 30, 2025, up from $332,455,081.
• Operating expenses surged by 131% to $188,966,002, primarily driven by a goodwill impairment charge of $170,419,429.
• Gedi Cube B.V., an indirect subsidiary, was declared bankrupt on September 2, 2025, due to inability to make payments.
• The company completed a 1-for-10 reverse stock split effective September 29, 2025.
• Lunai Bioworks operates through three subsidiaries: Renovaro Biosciences (cell and gene therapies), Renovaro Cube (AI-driven cancer detection), and BioSymetrics (biomedical AI for drug discovery and precision medicine).
• The company acquired BioSymetrics Inc. on April 8, 2025, issuing 15,000,000 shares of common stock valued at $6,058,500.
• An exchange agreement on July 7, 2025, converted $9.7 million in secured promissory notes into $16.1 million in new convertible promissory notes, which were immediately converted into 53.6 million common shares at $0.30 per share, without cash proceeds to the company.
• The company continues to incur substantial losses as a pre-clinical-stage biotechnology company with no products approved for regulatory sale and has not generated any revenues to date.
• Management has streamlined the organization to focus on its AI-driven cancer diagnostics platform and oncology therapeutic vaccine development.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a substantial increase in net loss, critically low cash reserves, a 'going concern' warning, and a subsidiary's bankruptcy. While there are strategic acquisitions and ongoing R&D, these are overshadowed by significant operational and legal challenges, and a heavy reliance on dilutive financing. The overall outlook is highly negative.

Positives

• The company successfully restructured $9.7 million in secured indebtedness through an exchange agreement, converting it into convertible notes and then common stock, providing some debt flexibility.
• Acquisition of BioSymetrics Inc. is expected to enhance data repository, biomarker discovery, in vivo validation, and drug discovery capabilities.
• Renovaro Cube's AI platform focuses on early cancer detection, recurrence monitoring, personalized treatment selection, and clinical trial support, leveraging multi-omics and Explainable AI.
• BioSymetrics' Contingent AI and Phenograph™ platform offer unique approaches to drug discovery and target identification, particularly for neurological diseases, with demonstrated efficacy in a mouse seizure model for a hit compound (BioS_831).

Negatives

• Net loss increased by 101% to $178,007,489 for the fiscal year 2025.
• Cash and cash equivalents are critically low at $92,700 as of June 30, 2025.
• The company has an accumulated deficit of over $510 million and a working capital deficit of $28.1 million, raising substantial doubt about its ability to continue as a going concern.
• Goodwill impairment of $170,419,429 was recorded, primarily due to the decline in the estimated fair value of the RENC reporting unit (Renovaro Cube) based on the company's market capitalization and inability to raise capital.
• Research and development expenses decreased by 80% to $537,428, partly due to discontinued product candidates (pan-coronavirus and influenza pipelines).
• An indirect subsidiary, Gedi Cube B.V., was declared bankrupt on September 2, 2025.
• Multiple ongoing legal proceedings, including securities class actions and derivative lawsuits, are diverting management attention and incurring significant legal expenses.
• Internal controls over financial reporting were deemed not effective due to inadequate resources for complex accounting matters.
• The company has never generated sales revenue and does not anticipate doing so until products are approved for marketing and sale, which is uncertain.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and dependence on additional financing.
• Failure to obtain necessary additional capital could force delays, limits, reductions, or termination of product development or commercialization efforts.
• Raising additional capital through equity issuance will dilute existing stockholders' ownership interests.
• Ongoing legal proceedings, regulatory investigations, and negative publicity related to a co-founder's conviction could incur significant expenses, divert management's attention, and harm business and reputation.
• As a pre-clinical biotechnology company, there is no assurance of successfully developing marketable products or generating revenue, potentially leading to suspension or cessation of operations.
• The market for AI-based healthcare solutions is new and unproven, with potential for limited growth or hindered adoption due to concerns over AI use and evolving regulations.
• Results of pre-clinical studies are not necessarily predictive of future clinical trial results, and failure to demonstrate efficacy could materially adversely affect business prospects.
• Reliance on third parties for research, development, and manufacturing may result in delays or failures if they do not perform their obligations.
• Limited experience in drug development means the company may not successfully develop any drugs, potentially leading to cessation of therapeutic development activities.
• Breach of intellectual property license agreements could lead to loss of critical IP rights.
• Inability to obtain and maintain sufficient intellectual property protection or broad scope of protection could adversely affect commercialization and competitive position.
• Third-party claims of intellectual property infringement could prevent or delay development and commercialization efforts, leading to substantial costs and liabilities.
• Challenges relating to the development and use of AI, including generative AI, could result in competitive harm, reputational harm, and legal liability.
• Limited corporate infrastructure and difficulties in managing growth could strain resources and delay development.
• Significant turnover in management and executive leadership creates uncertainty and could harm the ability to operate effectively.
• Serious adverse events or undesirable side effects attributable to product candidates could delay clinical development and commercialization.
• The stock price has been and is likely to remain volatile, potentially declining regardless of operating performance.
• Sales of a substantial number of common stock shares in the public market could cause the stock price to fall.
• Future sales and issuances of common stock or rights to purchase common stock will result in additional dilution.
• Economic, political, regulatory, and other risks associated with international operations, including challenges in enforcing intellectual property rights in foreign jurisdictions.
• Product or professional liability claims due to errors in test results or product performance could lead to substantial liabilities and reputational damage.

Future Outlook

The company anticipates continued substantial and increasing losses for the foreseeable future as it invests in research, development, and seeks regulatory approvals for product candidates. It expects to expend substantial resources for pre-clinical development of cell, gene, and immunotherapy product candidates, and the advancement of its AI-driven healthcare technology. Future capital requirements are highly uncertain and depend on the costs of clinical studies, regulatory approvals, commercialization, and intellectual property protection. The company plans to secure additional funding through equity or debt financing, but there is no assurance of availability or reasonable terms, which could lead to material reduction or suspension of operations.

Management Comments

• Management has reduced overhead and administrative costs by streamlining the organization to focus on the development and validation of its AI-driven cancer diagnostics platform.
• The company intends to attempt to secure additional required funding through equity or debt financing, acknowledging that such funding may not be available or on reasonable terms.
• If sufficient funds are not obtained, cash resources will be depleted, potentially requiring material reduction or suspension of operations, or even bankruptcy protection.

Industry Context

Lunai Bioworks operates in the highly competitive and rapidly evolving fields of biotechnology and AI-driven healthcare technology. Its Renovaro Biosciences subsidiary is in the pre-clinical stage of developing allogeneic cell and gene therapies for cancer, a field with high upfront capital expenditures and significant regulatory hurdles. Renovaro Cube and BioSymetrics compete in the AI-driven diagnostics and drug discovery markets, facing established players like Grail, Freenome, Owkin, Recursion Pharma, and insitro. The industry is characterized by rapid technological change, intense competition for talent, and increasing regulatory scrutiny, particularly for novel AI-based and gene/cell therapy products. The company's focus on Explainable AI and multi-omics integration aims to differentiate it in a crowded market, but the unproven nature of AI in healthcare and evolving regulatory landscape pose significant challenges.

Comparison to Industry Standards

• Lunai Bioworks' pre-clinical stage for therapeutic candidates (RENB-DC11, RENB-DC20, BioS_831) is typical for early-stage biotechnology companies, but the substantial and increasing losses, coupled with a 'going concern' warning, indicate a financial position significantly below industry standards for sustainable operations.
• In AI-driven diagnostics, competitors like Grail, Freenome, and Owkin are more established, often with more advanced clinical validation and market presence. Lunai's 'Explainable AI' and 'differential diagnosis' are presented as differentiators, but their commercialization is nascent and unproven against these benchmarks.
• For phenotype-based profiling and drug discovery, BioSymetrics competes with companies like Recursion Pharma and insitro. BioSymetrics claims differentiation through multicellular/multi-organ phenotypes and higher experimental throughput using zebrafish models compared to murine models, targeting an earlier stage of compound screening. However, the financial resources and market penetration of these larger competitors set a high bar for Lunai's subsidiaries.

Management Changes

Corporate Governance

Legal Proceedings

• Securities Class Action Litigation (Chow Action): Filed July 26, 2022, alleging false and misleading statements related to Serhat Gmrkc and commercial prospects. Motion to dismiss denied June 28, 2024. Settlement stipulation signed September 17, 2024, with preliminary approval granted August 18, 2025.
• Federal Derivative Litigation (Koenig Matter): Filed September 22, 2022, alleging violations of Exchange Act Sections 14(a) and 20(a), breach of fiduciary duty, and gross mismanagement. Stayed January 24, 2023, then again July 14, 2025, until October 17, 2025.
• Federal Derivative Litigation (Solak Matter): Filed January 19, 2023, similar allegations to Koenig Matter. Stayed April 6, 2023, then again July 29, 2025, for 90 days.
• State Derivative Litigation (Midler Matter): Filed October 20, 2022, similar allegations to federal derivative actions. Stayed January 20, 2023, then again July 31, 2025, for 120 days.
• Company's Complaint against Serhat Gmrkc, William Anderson Wittekind, G Tech Bio, SG & AW Holdings, LLC, and SRI: Filed October 21, 2022, alleging a fraudulent scheme to falsify study results for Hepatitis B and SARS-CoV-2/influenza pipelines, resulting in $25 million in payments. Defendants filed a cross-complaint seeking termination of license agreements. Trial date reset from March 3, 2025, to November 30, 2026.
• Weird Science LLC, Wittekind, and Trusts vs. Company: Filed June 7, 2023, alleging breach of Investor Rights Agreement, fraud, and tortious interference. Court dismissed some claims on November 15, 2024, and February 26, 2025, but denied dismissal of breach of contract claims related to 2020 and 2022 registration statements.
• Shareholder Derivative Action by Weird Science and Wittekind: Filed January 23, 2024, alleging violations of Exchange Act Sections 13(d) and 14(a), breach of fiduciary duty, corporate waste, and unjust enrichment. Dismissed without prejudice on October 29, 2024, but an appeal was filed November 27, 2024.
• Company's Suit against Weird Science, Gumrukcu, Wittekind, and Trusts: Filed June 21, 2024, alleging fraudulent concealment of a murder-for-hire scheme to induce a 2018 merger. Defendants moved to dismiss on October 1, 2024, with a hearing held June 25, 2025.
• Lunai vs. Predictive Oncology, Inc. (POAI): Lunai commenced action claiming POAI breached a January 2025 Letter Agreement for acquisition, making it impossible and devaluing Lunai's stock. Action held in abeyance for settlement negotiations.

Related Party Transactions

• Paseco ApS (Danish entity controlled by a shareholder) and Laksya Ventures Inc. are involved in bridge loans and promissory notes totaling $3,450,000 and $2,650,000, respectively, with 10% interest rates.
• Paseco ApS and Laksya Ventures Inc. also hold promissory notes from Renovaro Cube totaling approximately $490,000.
• RS Bio ApS (Danish entity controlled by a shareholder) and Rene Sindlev (assignee of RS Bio) hold promissory notes totaling $100,000, $105,263, $526,315, and $750,000 with 12% interest rates.
• The Promissory Note for $831,497 (originally $5,000,000) was issued to Paseco ApS and later assigned to Rene Sindlev.
• The company has accrued $384,949 of compensation-related expenses for its former Chief Executive Officer, Mark Dybul, due to budget constraints.
• Avram Miller, a former board member, forfeited shares and was granted stock options as part of a modification to his advisory services compensation.

Stakeholder Impact

• Shareholders: Significant dilution from past and potential future equity issuances, substantial losses, and a 'going concern' warning negatively impact investment value. The 1-for-10 reverse stock split may temporarily increase share price but does not address underlying financial issues. Ongoing legal disputes create uncertainty and potential liabilities.
• Employees: Management turnover and the need to attract highly skilled personnel in a competitive market could affect stability and growth. Streamlining operations and workforce tailoring may lead to job insecurity or changes.
• Customers/Partners: The bankruptcy of a subsidiary (Gedi Cube B.V.) and the company's financial instability could erode confidence in its ability to deliver on products and services, particularly for its AI-driven diagnostic platforms.
• Creditors: The company's 'going concern' status and reliance on debt financing, some from related parties, indicate elevated risk for creditors. The debt restructuring through the Exchange Agreement provided some relief but also involved a significant premium.
• Regulatory Authorities: The 'not effective' assessment of internal controls over financial reporting could lead to increased scrutiny and potential enforcement actions. Compliance with evolving AI and medical device regulations will be critical and costly.

Next Steps

• Obtain additional funding through equity or debt financing to continue operations and fund research and development.
• Continue clinical and regulatory work to develop product candidates (RENB-DC11, RENB-DC20, BioS_831).
• Build working capital reserves.
• Expand in-kind contribution projects with hospitals, research centers, and pharmaceutical companies for Renovaro Cube.
• Develop long-term strategic partnerships for multi-modal analysis and revenue streams for Renovaro Cube.
• Develop Renovaro Cube's multi-modal, multi-omics platform architecture and first prototypes.
• Build Renovaro Cube's service and support models for its AI platform.
• Build or lease a supercomputer for genomic data processing and algorithm training.
• Continue business development in EMEA (UK, Netherlands, Germany) and expand to the US for Renovaro Cube.
• Deploy a sequencing lab in the EMEA region for Renovaro Cube to control sample preparation and quality control.
• Expand Renovaro Cube's team to include biomedical scientists, data scientists, machine-learning engineers, specialized medical doctors, high-performance-computer engineers, and software engineers.
• Establish state-of-the-art fully certified service laboratories (CLIA and ISO standards) in the Netherlands, expanding to other EU, US, and global sites, to provide multi-omic sequencing services and acquire data.
• Contest ongoing legal proceedings and vigorously defend against cross-claims.

Key Dates

Recommendation

Lunai Bioworks Inc. is in a precarious financial position, marked by a 101% increase in net loss, critically low cash reserves, and an accumulated deficit exceeding half a billion dollars. The 'going concern' warning from auditors indicates a high risk of business failure without substantial, uncertain future financing. The bankruptcy of a key subsidiary (Gedi Cube B.V.) and the significant goodwill impairment further underscore severe operational and valuation challenges. Multiple ongoing legal proceedings, including fraud allegations against a co-founder, create substantial legal and reputational risks, diverting critical resources. While the company has strategic acquisitions and promising pre-clinical programs, these are overshadowed by its inability to generate revenue, ineffective internal controls, and heavy reliance on dilutive financing. The recent 1-for-10 reverse stock split is a cosmetic measure that does not address the fundamental financial instability. Given the high risk of further dilution, potential cessation of operations, and a highly uncertain path to profitability, a seasoned investor would likely recommend a strong sell.

Keywords

Biotechnology, AI-driven healthcare, Cancer diagnostics, Cell therapy, Gene therapy, Immunotherapy, Precision medicine, Drug discovery, SEC filing, 10-K, Financial reporting, Goodwill impairment, Going concern, Legal proceedings, Stock split, NASDAQ